# A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595

> **NCT02134834** · PHASE1 · COMPLETED · sponsor: **Meiji Seika Pharma Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Healthy Volunteers
- Bacterial Infections

## Interventions

- **DRUG:** OP0595
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02134834
- **Lead sponsor:** Meiji Seika Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-08
- **Final completion:** 2014-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02134834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02134834, "A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02134834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*